74
Participants
Start Date
February 19, 2021
Primary Completion Date
January 18, 2023
Study Completion Date
January 18, 2023
efanesoctocog alfa (BIVV001)
Pharmaceutical form: solution for injection Route of administration: IV
Investigational Site Number :1580001, Taichung
Investigational Site Number :1580003, Taichung
Investigational Site Number :0360001, Westmead
Investigational Site Number :0360002, South Brisbane
Investigational Site Number :3480005, Pécs
Investigational Site Number :7560001, Zurich
Investigational Site Number :1580002, Taipei
NY Presbyterian - Weill Cornell Medical Center-Site Number:8400020, New York
Investigational Site Number :1580004, Taipei
Investigational Site Number :3800001, Milan
Investigational Site Number :7520001, Malmo
East Carolina University/Brody Medical Sciences Building-Site Number:8400015, Greenville
Investigational Site Number :7240001, Madrid
Children's Healthcare of Atlanta-Site Number:8400019, Atlanta
University of Florida-Site Number:8400009, Gainesville
Investigational Site Number :7920001, Istanbul
Childrens Hospital Of Columbus-Site Number:8400012, Columbus
Cincinnati Children's Hospital Medical Center-Site Number:8400008, Cincinnati
University of Iowa Hospitals and Clinics-Site Number:8400002, Iowa City
Investigational Site Number :2500003, Lille
Investigational Site Number :2760001, Frankfurt am Main
Investigational Site Number :2500004, Bron
Investigational Site Number :3800002, Napoli
Investigational Site Number :2760002, München
Children's Hospital Los Angeles-Site Number:8400006, Los Angeles
Investigational Site Number :2500001, Le Kremlin-Bicêtre
Rush University Medical Center-Site Number:8400001, Chicago
Children's Hospital Of Wisconsin-Site Number:8400005, Milwaukee
Investigational Site Number :1240004, Hamilton
Investigational Site Number :1240003, London
Investigational Site Number :1240002, Ottawa
Investigational Site Number :1240001, Toronto
Investigational Site Number :3720001, Dublin
Investigational Site Number :5280002, Amsterdam
Investigational Site Number :5280001, Utrecht
Investigational Site Number :7240002, Esplugues de Llobregat
Investigational Site Number :7920004, Antalya
Investigational Site Number :7920003, Izmir
Investigational Site Number :8260003, Birmingham
Investigational Site Number :8260001, London
Bioverativ, a Sanofi company
INDUSTRY